Plague vaccines: new developments in an ongoing search
- PMID: 34142207
- PMCID: PMC8211537
- DOI: 10.1007/s00253-021-11389-6
Plague vaccines: new developments in an ongoing search
Abstract
As the reality of pandemic threats challenges humanity, exemplified during the ongoing SARS-CoV-2 infections, the development of vaccines targeting these etiological agents of disease has become increasingly critical. Of paramount concern are novel and reemerging pathogens that could trigger such events, including the plague bacterium Yersinia pestis. Y. pestis is responsible for more human deaths than any other known pathogen and exists globally in endemic regions of the world, including the four corners region and Northern California in the USA. Recent cases have been scattered throughout the world, including China and the USA, with serious outbreaks in Madagascar during 2008, 2013-2014, and, most recently, 2017-2018. This review will focus on recent advances in plague vaccine development, a seemingly necessary endeavor, as there is no Food and Drug Administration-licensed vaccine available for human distribution in western nations, and that antibiotic-resistant strains are recovered clinically or intentionally developed. Progress and recent development involving subunit, live-attenuated, and nucleic acid-based plague vaccine candidates will be discussed in this review. KEY POINTS: • Plague vaccine development remains elusive yet critical. • DNA, animal, and live-attenuated vaccine candidates gain traction.
Keywords: DNA vaccines; Humoral; Live attenuated; Protection; Protein subunit.
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.mBio. 2021 Dec 21;12(6):e0322321. doi: 10.1128/mBio.03223-21. Epub 2021 Dec 7. mBio. 2021. PMID: 34872353 Free PMC article.
-
Live-attenuated Yersinia pestis vaccines.Expert Rev Vaccines. 2013 Jun;12(6):677-86. doi: 10.1586/erv.13.42. Expert Rev Vaccines. 2013. PMID: 23750796 Review.
-
Developing live vaccines against plague.J Infect Dev Ctries. 2011 Sep 14;5(9):614-27. doi: 10.3855/jidc.2030. J Infect Dev Ctries. 2011. PMID: 21918302 Free PMC article. Review.
-
Rational considerations about development of live attenuated Yersinia pestis vaccines.Curr Pharm Biotechnol. 2013;14(10):878-86. doi: 10.2174/1389201014666131226122243. Curr Pharm Biotechnol. 2013. PMID: 24372254 Free PMC article. Review.
-
An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.PLoS Negl Trop Dis. 2012;6(2):e1528. doi: 10.1371/journal.pntd.0001528. Epub 2012 Feb 14. PLoS Negl Trop Dis. 2012. PMID: 22348169 Free PMC article.
Cited by
-
Current Progress in the Development of mRNA Vaccines Against Bacterial Infections.Int J Mol Sci. 2024 Dec 6;25(23):13139. doi: 10.3390/ijms252313139. Int J Mol Sci. 2024. PMID: 39684849 Free PMC article. Review.
-
Live Plague Vaccine Development: Past, Present, and Future.Vaccines (Basel). 2025 Jan 13;13(1):66. doi: 10.3390/vaccines13010066. Vaccines (Basel). 2025. PMID: 39852845 Free PMC article. Review.
-
Biological threat preparedness through vaccine development and stockpiling: challenges and strategic implications.Front Public Health. 2025 Jun 2;13:1614626. doi: 10.3389/fpubh.2025.1614626. eCollection 2025. Front Public Health. 2025. PMID: 40529698 Free PMC article. Review.
-
Protection Induced by Oral Vaccination with a Recombinant Yersinia pseudotuberculosis Delivering Yersinia pestis LcrV and F1 Antigens in Mice and Rats against Pneumonic Plague.Infect Immun. 2022 Aug 18;90(8):e0016522. doi: 10.1128/iai.00165-22. Epub 2022 Jul 28. Infect Immun. 2022. PMID: 35900096 Free PMC article.
-
Evaluation of human antibodies from vaccinated volunteers for protection against Yersinia pestis infection.Microbiol Spectr. 2024 Oct 3;12(10):e0105424. doi: 10.1128/spectrum.01054-24. Epub 2024 Aug 27. Microbiol Spectr. 2024. PMID: 39189763 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous